Lumithera, Inc.

Lumithera, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases, specifically dry age-related macular degeneration (AMD). LumiThera is the leader in ophthalmic photobiomodulation (PBM) innovation with its flagship product, the Valeda® Light Delivery System. Multiwavelength Valeda treatments are for patients suffering from dry AMD. Valeda is FDA Authorized in the US, CE Marked in the EU, and available in select countries in Latin America. AdaptDx Pro® is a portable dark adaptometer that utilizes AI to deliver a uniform patient experience. AdaptDx Pro is available in the U.S. and Canada. NOVA Vision Testing System is a comprehensive electrophysiology platform that provides objective assessment of the entire pathway for visual and neuro-visual disorders. VEP is available in the U.S. and select countries outside of the U.S. ERG is only available outside of the U.S. For more information on Valeda, visit www.lumithera.com. AdaptDx Pro and NOVA are available through LumiThera Diagnostics, Inc. and Diopsys, Inc., respectively.

Company Details

Employees
45
Address
19578 10th Avenue Ne, Suite 200, Poulsbo,washington 98370,united States
Phone
+44-2076601516
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Poulsbo, Washington
Looking for a particular Lumithera, Inc. employee's phone or email?

Lumithera, Inc. Questions

News

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) - Business Wire

Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) Business Wire

Alcon To Acquire LumiThera - citybiz

Alcon To Acquire LumiThera citybiz

LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects - Business Wire

LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects Business Wire

Alcon snaps up LumiThera for light-based AMD treatment - Optics.org

Alcon snaps up LumiThera for light-based AMD treatment Optics.org

Alcon completes acquisition of LumiThera - Ophthalmology Times

Alcon completes acquisition of LumiThera Ophthalmology Times

LumiThera launches European registry study into AMD light therapy - Clinical Trials Arena

LumiThera launches European registry study into AMD light therapy Clinical Trials Arena

LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System - Optometry Times

LumiThera announces top-line results from LIGHTSITE IIIB extension trial assessing the Valeda Light Delivery System Optometry Times

Eye care giant Alcon acquires LumiThera, a Seattle-area startup behind device that treats vision loss - GeekWire

Eye care giant Alcon acquires LumiThera, a Seattle-area startup behind device that treats vision loss GeekWire

Alcon to buy LumiThera’s light-based therapy for dry AMD - Fierce Biotech

Alcon to buy LumiThera’s light-based therapy for dry AMD Fierce Biotech

Alcon officially purchases LumiThera - Eyes On Eyecare

Alcon officially purchases LumiThera Eyes On Eyecare

Photobiomodulation Treatment Receives FDA Authorization for Dry AMD Therapy - Ophthalmology Advisor

Photobiomodulation Treatment Receives FDA Authorization for Dry AMD Therapy Ophthalmology Advisor

LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects - PR Newswire

LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects PR Newswire

Alcon Acquires LumiThera, Adds Noninvasive Solution | BioScan | Sep/Oct 2025 - Photonics Spectra

Alcon Acquires LumiThera, Adds Noninvasive Solution | BioScan | Sep/Oct 2025 Photonics Spectra

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision - Business Wire

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision Business Wire

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD Ophthalmology Times

FDA clears its first treatment for dry AMD, with LumiThera's light-based Valeda system - Fierce Biotech

FDA clears its first treatment for dry AMD, with LumiThera's light-based Valeda system Fierce Biotech

Medical device startup LumiThera raises $14M to further develop treatment for ocular disorders - GeekWire

Medical device startup LumiThera raises $14M to further develop treatment for ocular disorders GeekWire

LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy - PR Newswire

LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy PR Newswire

New company OpZira formed following Alcon’s acquisition of LumiThera - Ophthalmology Times

New company OpZira formed following Alcon’s acquisition of LumiThera Ophthalmology Times

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement - Business Wire

LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement Business Wire

Photobiomodulation For Dry AMD: Ready For Its Day in The Sun? - Ophthalmology Advisor

Photobiomodulation For Dry AMD: Ready For Its Day in The Sun? Ophthalmology Advisor

Alcon Acquires LumiThera to Boost Dry AMD Treatment Options - WebProNews

Alcon Acquires LumiThera to Boost Dry AMD Treatment Options WebProNews

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda ® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD) - Via TT

LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda ® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD) Via TT

Valeda Light Delivery System Receives 2019 Medical Design Excellence Award - PR Newswire Canada

Valeda Light Delivery System Receives 2019 Medical Design Excellence Award PR Newswire Canada

Diabetic Retinopathy is Preventable Vision Loss with These Latest Tools and Treatments - InvisionMag.com

Diabetic Retinopathy is Preventable Vision Loss with These Latest Tools and Treatments InvisionMag.com

Top Lumithera, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant